You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Gary J. Nabel, new chief scientific officer for Sanofi, will be based in Cambridge

French pharmaceutical giant Sanofi SA, which bought Genzyme Corp. in 2011, said Wednesday that its new chief scientific officer is Gary J. Nabel, a medical doctor with ties to Harvard University and the Massachusetts Institute of Technology.

Nabel’s appointment takes effect Dec. 3, and he will be based in Cambridge, Sanofi said. Nabel will report to Dr. Elias Zerhouni, Sanofi’s president for global research and development.

Continue reading below

Since buying Genzyme for $20.1 billion, Sanofi has looked to make the Boston area its top US research hub.

Nabel joins Sanofi from the National Institutes of Health, where he served as director of the Vaccine Research Center. Nabel has degrees from Harvard, including a Ph.D. and a medical degree. He served as a postdoctoral fellow in the laboratory of David Baltimore at MIT’s Whitehead Institute, according to Sanofi’s press release.

“In his new position, Dr. Nabel will be responsible for assessing and coordinating Sanofi’s scientific direction for biopharmaceuticals, vaccines, and animal health with a focus on improving translational approaches across Sanofi,” the Sanofi release said.

In March, Sanofi chief executive Christopher A. Viehbacher addressed the Boston College Chief Executives’ Club.

Sanofi is using its newly expanded presence in the Boston area to pioneer a research model that relies more on partnerships with outside innovators and less on its in-house efforts, Viebacher said then. Greater Boston’s focus on innovation makes it a perfect location to collaborate on drug development with academic researchers and biotech start-ups, he added.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.